Press Release
Dimension Bio CEO Featured on Prime Movers Lab Podcast Highlighting Breakthrough Tissue Therapeutics
CHICAGO, Illinois, USA – September 23, 2025 – Dimension Bio, a biotechnology company pioneering regenerative tissue therapeutics, announced today that Chief Executive Officer Caralynn Nowinski Collens, M.D. is featured on the Prime Movers Lab Podcast, a series that highlights visionary founders and researchers advancing breakthrough science and technology.
In the episode, “Revolutionizing Tissue Therapeutics w/ Dimension Bio CEO Caralynn Nowinski Collens, M.D.”, Collens shares Dimension Bio’s mission to develop life-saving regenerative therapies, with an initial focus on treating patients facing acute liver failure. She discusses her path as a physician-turned-entrepreneur, the urgent and growing need for effective liver disease treatments, and the company’s innovative BioNidum™ platform for cell-based therapeutics.
The conversation also explores Dimension Bio’s recent scientific and clinical milestones, how its tissue-therapeutic approach is differentiated from traditional small molecules and cell-only solutions, as well as the broader regulatory and market dynamics shaping the future of regenerative medicine.
“Dimension Bio was founded on the belief that cells need the right environment to unlock their full therapeutic potential,” said Collens. “It was a privilege to join the Prime Movers Lab podcast to share our story and discuss how we are working to bring transformative therapies to patients who today have very limited treatment options.”
Prime Movers Lab partners with companies that are working to transform billions of lives through breakthrough technologies in fields such as life sciences, energy, transportation, and space.
Listen to the full episode here: Apple Podcasts Link
+ About Dimension Bio
Dimension Bio is a biotechnology company pioneering regenerative therapeutics. We design lifesaving solutions that restore organ function lost to disease, trauma or aging. Our bioinspired cell delivery system, BioNidum™, fuses materials science, 3D-printing, and digital manufacturing to transform cells into implantable, tissue-like therapies.
By providing a three-dimensional architecture that promotes rapid vascularization and seamless tissue integration, our tissue therapeutics create the conditions cells need to survive, function, and persist. The result is a more durable and effective therapeutic response—unlocking the curative potential of cell therapies.
Our lead program targets liver failure, providing immediate supplemental liver function to stabilize patients in crisis. By enabling the native liver to recover, it offers an alternative to transplant and fills a critical gap for those with limited treatment options.